এস্তোনিয়া - এস্তোনীয় - Ravimiamet

menarini international operations luxembourg s.a. - lerkanidipiin - õhukese polümeerikattega tablett - 10mg 35tk; 10mg 60tk; 10mg 100tk; 10mg 98tk; 10mg 90tk; 10mg 56tk; 10mg 28tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

pharmaceutical works polpharma s.a. - karvedilool - õhukese polümeerikattega tablett - 25mg 30tk; 25mg 60tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

pharmaceutical works polpharma s.a. - karvedilool - õhukese polümeerikattega tablett - 6,25mg 60tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

pharmaceutical works polpharma s.a. - karvedilool - õhukese polümeerikattega tablett - 12,5mg 60tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

accord healthcare b.v. - lerkanidipiin - õhukese polümeerikattega tablett - 20mg 28tk; 20mg 30tk; 20mg 50tk; 20mg 100tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

accord healthcare b.v. - lerkanidipiin - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 90tk; 10mg 14tk; 10mg 10tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

ideal trade links uab - lerkanidipiin - õhukese polümeerikattega tablett - 10mg 35tk; 10mg 56tk; 10mg 90tk; 10mg 28tk; 10mg 100tk; 10mg 60tk; 10mg 7tk; 10mg 50tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - budesonide/formoterol teva on näidustatud täiskasvanutele 18-aastased ja vanemad ainult. asthmabudesonide/formoterol teva on näidustatud regulaarne astma raviks, kui kasutada kombinatsiooni (inhaleeritava kortikosteroidi ja pika toimeajaga β2 adrenoceptor agonist) on asjakohane:patsientidel ei ole piisavalt kontrollitud inhaleeritava kortikosteroide ja "nii nagu vaja" sisse hingata lühikese toimeajaga β2 adrenoceptor agonistid. orin patsiendid juba piisavalt kontrollitud, nii inhaleeritava kortikosteroide ja pika toimeajaga β2 adrenoceptor agonistid. copdsymptomatic patsientide ravi raske copd (fev1 < 50% prognoositav tavaline) ja ajaloo korduvad ägenemised, kes on märkimisväärne sümptomid hoolimata regulaarne ravi pika toimeajaga bronhodilataatorite.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).